Tuberculosis

At Johnson & Johnson, our top priority is developing and delivering medicines to all patients in need. We stand committed to working closely with countries and other partners to rapidly scale up access to bedaquiline and reach all eligible patients.

— Paul Stoffels, M.D., Vice Chair of the Executive Committee and Chief Scientific Officer

TB is an often-overlooked area in global health, and our 10-Year Initiative aims to change that. We’re working and partnering in new and unprecedented ways to modernize treatment, improve patient-finding and connect more patients with care – all with the goal of ending TB once and for all.

— Martin Fitchet, Global Head, Global Public Health, Johnson & Johnson

The greatest opportunity to accelerate the fight against TB is right now in this new decade.

— Ana-Maria Ionescu, Global Marketing Leader, Tuberculosis, Global Public Health

It's not until that very last patient is cured that I'll feel rested, until then I'll continue to do what I do.

— Chrispin Kambili, Global Medical Affairs Leader, Tuberculosis, Global Public Health

What inspires me to fight TB is our mothers, our fathers, our patients, our nurses, our healthcare providers.

— Erwin Benedicto, Head of Medical Affairs, Johnson & Johnson Philippines

We can’t beat TB alone. That’s why we’re honored to join forces with our partners in the quest to create the first pan-TB treatment. Together, we can transform TB treatment and end this disease once and for all.

— Ruxandra Draghia-akli, M.D., Ph.D., Global Head, Global Public Health R&D

Johnson & Johnson is advancing the fight against TB by doing much beyond the pill. We are engaging with partners at the national and international levels to ensure that we work with them to build the capacity and the systems needed to ensure that treatment is accessible.

— Vandita Gupta, Franchise Head, Infectious Diseases and Vaccines, Janssen India

I'm committed to tackling TB because TB is a neglected disease. A lot of other diseases have gotten a lot of public focus ... I'm really committed to making it history. And we can. It's a curable disease.

— Koné Kaniga, Director, Project Scientist, TB, Janssen R&D

When we end TB, patients and families can go back to their normal lives. Then, we can apply and scale up learnings from TB elimination efforts to help more patients in other areas.

— Salinee Vongpanich, Regional Public Health Access Lead, Johnson & Johnson Southeast Asia